Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1356

1.

Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.

Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D.

Exp Hematol. 2007 Oct;35(10):1527-37. Epub 2007 Aug 13.

PMID:
17697742
2.

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.

Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC.

Blood. 2003 Jul 15;102(2):652-8. Epub 2003 Mar 20.

3.

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.

Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.

Apoptosis. 2006 Jul;11(7):1175-93.

PMID:
16699949
4.

Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.

Exp Cell Res. 2007 Jul 1;313(11):2378-88. Epub 2007 Mar 30.

PMID:
17462628
6.

2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.

Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Lowdell MW, Samuel ER, North JM, Nacheva EP, Chanalaris A, Kottaridis P, Cwynarski K, Wickremasinghe RG.

Blood. 2009 Aug 6;114(6):1217-25. doi: 10.1182/blood-2008-11-190587. Epub 2009 Jun 10.

7.

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM.

Oncogene. 2002 Oct 3;21(44):6809-18.

8.

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM.

Cell Death Differ. 2004 Dec;11 Suppl 2:S193-206.

9.

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, Fulda S.

Oncogene. 2009 Sep 3;28(35):3097-110. doi: 10.1038/onc.2009.161. Epub 2009 Jul 13.

PMID:
19597472
10.
11.

Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.

Jantus-Lewintre E, Sarsotti E, Terol MJ, Benet I, García-Conde J.

Clin Transl Oncol. 2006 Nov;8(11):805-11.

PMID:
17134969
12.

HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.

Morales JC, Ruiz-Magaña MJ, Carranza D, Ortiz-Ferrón G, Ruiz-Ruiz C.

Cancer Lett. 2010 Nov 1;297(1):91-100. doi: 10.1016/j.canlet.2010.04.029. Epub 2010 May 23.

PMID:
20580868
13.

The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.

McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M.

Cancer Res. 2009 Nov 1;69(21):8366-75. doi: 10.1158/0008-5472.CAN-09-0131. Epub 2009 Oct 13.

14.

Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.

Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L.

Br J Haematol. 2009 Jan;144(1):41-52. doi: 10.1111/j.1365-2141.2008.07426.x. Epub 2008 Nov 1.

PMID:
19006566
15.

Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.

Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9. Epub 2002 Mar 12.

16.

4-arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukemia patients.

Billard C, Menasria F, Quiney C, Faussat AM, Finet JP, Combes S, Kolb JP.

Exp Hematol. 2008 Dec;36(12):1625-33. doi: 10.1016/j.exphem.2008.07.008. Epub 2008 Oct 14.

PMID:
18922614
17.

Phorbol ester-induced PKCepsilon down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation.

Gobbi G, Mirandola P, Carubbi C, Micheloni C, Malinverno C, Lunghi P, Bonati A, Vitale M.

Blood. 2009 Mar 26;113(13):3080-7. doi: 10.1182/blood-2008-03-143784. Epub 2008 Nov 6.

18.

Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.

Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS.

Apoptosis. 2010 Oct;15(10):1256-69. doi: 10.1007/s10495-010-0521-9.

PMID:
20582477
20.

Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.

Iacomino G, Medici MC, Russo GL.

Anticancer Res. 2008 Mar-Apr;28(2A):855-64.

Items per page

Supplemental Content

Write to the Help Desk